DeucravacitinibSotyktu

The PBAC deferred making a recommendation for the listing of deucravacitinib for the treatment of severe chronic plaque psoriasis, to seek additional expert clinical advice on its appropriate and likely place in therapy. In deferring the matter, the PBAC was uncertain as to whether the proposed clinical place of deucravacitinib, in the same line of therapy as apremilast, i.e. after non- or inadequate 33PSD · Mar 2023

The PBAC noted the submission nominated apremilast as the primary comparator and considered that if the proposed place in therapy were accepted, apremilast was an appropriate comparator. However, the Committee considered that if deucravacitinib was more likely to be used in patients who are potentially eligible for biologics, these therapies may represent a more appropriate primary comparator.PSD · Mar 2023

The submission presented a cost-utility analysis. This is consistent with the claim of superior comparative clinical effectiveness and non-inferior safety of deucravacitinib versus apremilast in patients with severe CPP.PSD · Mar 2023

Table 9 provides a summary of the key components of the model. 19PSD · Mar 2023

The submission described deucravacitinib as superior in terms of efficacy compared with apremilast based on sPGA 0/1 score and PASI 75 at week 16. The ESC considered 18PSD · Mar 2023

However, in the POETYK 1 and POETYK 2 trials, 39% and 32% of patients had received prior biologic therapy, respectively, whereas the proposed Australian clinical management algorithm positions deucravacitinib before treatment with biologics.PSD · Mar 2023

The PBAC noted and welcomed the input from health care professionals (3) and organisations (1) via the Consumer Comments facility on the PBS website. The comments from health professionals noted patients with chronic plaque psoriasis often have poor quality of life due to their symptoms often being uncontrolled by topical treatments, and noted deucravacitinib is considered an option for this group to manage their symptoms and improve quality of life.PSD · Mar 2023

The PBAC also noted the advice from Creaky Joints Australia, which noted the impact of plaque psoriasis on patients’ lives and shared patient experiences of living with the condition. The experiences highlighted the physical and mental impacts of plaque psoriasis, including how the visible aspect of psoriasis leads to anxiety, depression and body image problems.PSD · Mar 2023